Status:
UNKNOWN
Novel Inflammatory Markers in Different Phenotypes of Severe Asthma
Lead Sponsor:
University of Pisa
Conditions:
Asthma
Nasal Polyps
Eligibility:
All Genders
18-65 years
Brief Summary
Asthma is a highly prevalent chronic airway inflammatory disease characterized by airway hyper-responsiveness, reversible airflow obstruction and increased mucus secretion, involving large and small a...
Eligibility Criteria
Inclusion
- Male or female
- age (18-65 years)
- Diagnosis of severe asthma according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) definition, with and without nasal symptoms
- normal pulmonary function post-therapy (FEV1 post-bronchodilation: greater than 80% of the predicted value, with FEV1/ vital capacity (VC) \> 88-89% - for males and females, respectively - of the predicted value)
- non reversible chronic airflow limitation (FEV1 post-bronchodilation: lower than 70% of the predicted value, with FEV1/VC \< 88-89% of the predicted value)
- Signing of the informed consent
Exclusion
- Referred Pregnancy
- Use of therapy with beta-blockers
- Smoking (current or within the previous 3 months)
- Negation to participate to the study
- Current upper and lower airways infectious diseases
- Current systemic infectious diseases
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04888910
Start Date
March 1 2021
End Date
February 28 2023
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pisa University
Pisa, Tuscany, Italy, 56126